Joinn Laboratories(China)Co.,Ltd. (SHA:603127)
China · Delayed Price · Currency is CNY | Market Cap | 33.72B +38.3% |
| Revenue (ttm) | 1.69B -7.9% |
| Net Income | 984.43M +223.0% |
| EPS | 1.33 +229.6% |
| Shares Out | 733.37M |
| PE Ratio | 36.94 |
| Forward PE | 48.87 |
| Dividend | 0.12 (0.24%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 55,401,802 |
| Open | 44.70 |
| Previous Close | 44.82 |
| Day's Range | 44.24 - 49.30 |
| 52-Week Range | 26.25 - 55.68 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 40.54 (-17.77%) |
| Earnings Date | Oct 29, 2026 |
About SHA:603127
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization s... [Read more]
Financial Performance
In 2025, SHA:603127's revenue was 1.66 billion, a decrease of -17.87% compared to the previous year's 2.02 billion. Earnings were 297.84 million, an increase of 302.08%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 603127 stock is "Buy." The 12-month stock price target is ¥40.54, which is a decrease of -17.77% from the latest price.
News
China needs monkeys: lab animal shortage could hinder biotech growth
China’s biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotec...